The Optipharm-CKM Programme
👤 Authors: Riccardo M Inciardi, Muthiah Vaduganathan, Carlo M Lombardi, Cristina Gussago, Piergiuseppe Agostoni, Pietro Ameri, Nadia Aspromonte, Leonardo Calò, Matteo Cameli, Erberto Carluccio, Stefano Carugo, Manlio Cipriani, Raffaele De Caterina, Gaetano M De Ferrari, Michele Emdin, Alessandra Fornaro, Marco Guazzi, Massimo Iacoviello, Massimo Imazio, Maria Teresa La Rovere, Sergio Leonardi, Marta Maccallini, Daniele Masarone, Luigi Moschini, Alberto Palazzuoli, Giuseppe Patti, Roberto F E Pedretti, Pasquale Perrone Filardi , Massimo F Piepoli, Luciano Potena, Andrea Salzano, Angela Sciacqua, Michele Senni, Gianfranco Sinagra, Claudia Specchia, Stefano Taddei, Dario Vizza, Gianluigi Savarese, Giuseppe Rosano, Maurizio Volterrani, Marco Metra; on behalf of the OPTIPHARM‐HF Investigators
ABSTRACT:
On behalf of the San Raffaele University (uniroma-5), the Italian Heart Failure Association (ITAHFA) and Heart Success Foundation (HFS)
The Optipharm Registry focuses on improving care for patients with cardiovascular, kidney, and metabolic conditions (CKM), which are closely linked and major causes of death and disability worldwide. These include heart disease, kidney disease, and type 2 diabetes. Many people with heart failure (HF) also have these conditions, especially those with mildly reduced or preserved heart function, and this can lead to worse health outcomes.
In 2023, the American Heart Association introduced a new framework called CKM syndrome to help identify and understand this overlap. Around 90% of adults in the U.S. have some form of CKM syndrome, with 15% experiencing more advanced stages. Treatment for CKM conditions has become more effective thanks to newer medications, but many patients are still not receiving the care they need, often due to issues like treatment delays, cost, or side effects.
The Optipharm Registry aims to collect real-world data to understand how these conditions are treated across different regions and how well current guidelines are being followed. By doing so, it will help identify barriers to effective treatment and improve patient care worldwide, focusing on heart disease, diabetes, kidney disease, and heart failure
About the OPTIPHARM-CKM Programme
The OPTIPHARM-CKM programme (Optimal Pharmacological Therapy Across the Cardio-Kidney-Metabolic Spectrum) is an international research initiative focused on improving care for people living with cardiovascular, kidney, and metabolic (CKM) diseases.
These conditions — including cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes (T2DM), and heart failure (HF) — are closely linked and often occur together. Patients with multiple CKM conditions are at higher risk of hospitalization, complications, and premature death. Despite advances in treatment and strong guideline recommendations, many patients worldwide still do not receive optimal medical therapy because of barriers such as delayed treatment, limited access to medications, contraindications, or medication intolerance.
The OPTIPHARM-CKM programme was created to better understand how these diseases are treated in real-world clinical practice across different countries and healthcare systems. The programme evaluates the use of evidence-based therapies across the cardiovascular spectrum, including newer treatments that benefit both heart and kidney health.
The project aims to:
- Assess how well guideline-recommended treatments are prescribed and maintained over time.
- Evaluate how therapies are introduced, adjusted, and optimized in routine care.
- Identify barriers that may prevent patients from receiving the best possible treatment.
- Study clinical outcomes such as heart failure hospitalizations, cardiovascular events, kidney complications, and cardiovascular mortality.
The programme includes patients with cardiovascular disease, chronic kidney disease, type 2 diabetes, and heart failure, providing a comprehensive view of care across the CKM spectrum.
By identifying treatment gaps and differences in care worldwide, OPTIPHARM-CKM aims to support better prevention strategies, improve multidisciplinary patient management, and ultimately enhance outcomes for people living with CKM conditions.
.
